Literature DB >> 1773950

Increased intestinal permeability in ankylosing spondylitis--primary lesion or drug effect?

A J Morris1, C W Howden, C Robertson, A Duncan, H Torley, R D Sturrock, R I Russell.   

Abstract

We have found increased small intestinal permeability to 51Cr-ethylenediaminetetra acetate in patients with ankylosing spondylitis compared with controls. There is no significant difference between patients with ankylosing spondylitis and patients with rheumatoid arthritis taking non-steroidal anti-inflammatory drugs (NSAID). The increased intestinal permeability in ankylosing spondylitis is independent of disease activity. These findings suggest that the increased permeability is caused by NSAID treatment and is probably not a primary lesion of small bowel mucosa.

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1773950      PMCID： PMC1379244          DOI： 10.1136/gut.32.12.1470

Source DB:  PubMed          Journal:  Gut        ISSN： 0017-5749            Impact factor:   23.059


  12 in total

1.  Ileocolonoscopy in seronegative spondylarthropathy.

Authors:  M De Vos; C Cuvelier; H Mielants; E Veys; F Barbier; A Elewaut
Journal:  Gastroenterology       Date:  1989-02       Impact factor: 22.682

2.  Intestinal permeability in ankylosing spondylitis.

Authors:  D Wendling; A Bidet; M Guidet
Journal:  J Rheumatol       Date:  1990-01       Impact factor: 4.666

3.  Lactulose, 51Cr-labelled ethylenediaminetetra-acetate, L-rhamnose and polyethyleneglycol 400 [corrected] as probe markers for assessment in vivo of human intestinal permeability.

Authors:  D G Maxton; I Bjarnason; A P Reynolds; S D Catt; T J Peters; I S Menzies
Journal:  Clin Sci (Lond)       Date:  1986-07       Impact factor: 6.124

4.  The leaky gut of alcoholism: possible route of entry for toxic compounds.

Authors:  I Bjarnason; T J Peters; R J Wise
Journal:  Lancet       Date:  1984-01-28       Impact factor: 79.321

5.  Raised titres of anti-klebsiella IgA in ankylosing spondylitis, rheumatoid arthritis, and inflammatory bowel disease.

Authors:  R Cooper; S M Fraser; R D Sturrock; C G Gemmell
Journal:  Br Med J (Clin Res Ed)       Date:  1988-05-21

6.  Mannitol estimation in biological fluids by gas-liquid chromatography of trimethylsilyl derivatives.

Authors:  M F Laker; J N Mount
Journal:  Clin Chem       Date:  1980-03       Impact factor: 8.327

7.  A persistent defect in intestinal permeability in coeliac disease demonstrated by a 51Cr-labelled EDTA absorption test.

Authors:  I Bjarnason; T J Peters; N Veall
Journal:  Lancet       Date:  1983-02-12       Impact factor: 79.321

8.  Intestinal permeability and inflammation in rheumatoid arthritis: effects of non-steroidal anti-inflammatory drugs.

Authors:  I Bjarnason; P Williams; A So; G D Zanelli; A J Levi; J M Gumpel; T J Peters; B Ansell
Journal:  Lancet       Date:  1984-11-24       Impact factor: 79.321

9.  Abnormal bowel permeability in ankylosing spondylitis and rheumatoid arthritis.

Authors:  M D Smith; R A Gibson; P M Brooks
Journal:  J Rheumatol       Date:  1985-04       Impact factor: 4.666

10.  Absorption of 51chromium-labeled ethylenediaminetetraacetate in inflammatory bowel disease.

Authors:  I Bjarnason; C O'Morain; A J Levi; T J Peters
Journal:  Gastroenterology       Date:  1983-08       Impact factor: 22.682
View more
  11 in total

Review 1.  Alterations in intestinal permeability.

Authors:  M C Arrieta; L Bistritz; J B Meddings
Journal:  Gut       Date:  2006-10       Impact factor: 23.059

2.  Enhanced jejunal production of antibodies to Klebsiella and other Enterobacteria in patients with ankylosing spondylitis and rheumatoid arthritis.

Authors:  O Mäki-Ikola; R Hällgren; L Kanerud; N Feltelius; L Knutsson; K Granfors
Journal:  Ann Rheum Dis       Date:  1997-07       Impact factor: 19.103

Review 3.  Uveitis and the gut microbiota.

Authors:  Shilpa Kodati; H Nida Sen
Journal:  Best Pract Res Clin Rheumatol       Date:  2020-04-09       Impact factor: 4.098

Review 4.  Intestinal permeability defects: is it time to treat?

Authors:  Matthew A Odenwald; Jerrold R Turner
Journal:  Clin Gastroenterol Hepatol       Date:  2013-07-12       Impact factor: 11.382

5.  Intestinal permeability in the ileal pouch.

Authors:  M N Merrett; N Soper; N Mortensen; D P Jewell
Journal:  Gut       Date:  1996-08       Impact factor: 23.059

6.  Distinctive gut microbiomes of ankylosing spondylitis and inflammatory bowel disease patients suggest differing roles in pathogenesis and correlate with disease activity.

Authors:  P R Sternes; L Brett; J Phipps; F Ciccia; T Kenna; E de Guzman; K Zimmermann; M Morrison; G Holtmann; E Klingberg; D Mauro; C McIvor; H Forsblad-d'Elia; M A Brown
Journal:  Arthritis Res Ther       Date:  2022-07-07       Impact factor: 5.606

Review 7.  The role of the microbiome in rheumatic diseases.

Authors:  Nigel Yeoh; Jeremy P Burton; Praema Suppiah; Gregor Reid; Simon Stebbings
Journal:  Curr Rheumatol Rep       Date:  2013-03       Impact factor: 4.592

8.  The colon in patients with ankylosing spondylitis and in normal controls in Bangladesh: a macroscopic and microscopic study.

Authors:  Md Nazrul Islam; Mir Mahfuzul Hoque Chowdhury; Syed Atiqul Haq; Mohammad Kamal; Anwarul Kabir; Mahmud Hasan; Johannes J Rasker
Journal:  Clin Rheumatol       Date:  2009-10-21       Impact factor: 2.980

Review 9.  Non-invasive investigation in patients with inflammatory joint disease.

Authors:  Elisabetta Dal Pont; Renata D'Incà; Antonino Caruso; Giacomo-Carlo Sturniolo
Journal:  World J Gastroenterol       Date:  2009-05-28       Impact factor: 5.742

Review 10.  Faecal blood loss with aspirin, nonsteroidal anti-inflammatory drugs and cyclo-oxygenase-2 selective inhibitors: systematic review of randomized trials using autologous chromium-labelled erythrocytes.

Authors:  R Andrew Moore; Sheena Derry; Henry J McQuay
Journal:  Arthritis Res Ther       Date:  2008-01-17       Impact factor: 5.156
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.